Portal de Periódicos da CAPES

Recent developments in the treatment of advanced bladder cancer

2018; Elsevier BV; Volume: 36; Issue: 3 Linguagem: Inglês

10.1016/j.urolonc.2017.12.018

1873-2496

James Luke Godwin, Jean H. Hoffman-Censits, Elizabeth R. Plimack,

Cancer Immunotherapy and Biomarkers

Urothelial carcinoma of the bladder is a common malignancy which has historically been difficult to treat in its advanced stages. Clinically effective treatment options for locally advanced/inoperable or metastatic urothelial carcinoma (mUC) consisted of cisplatin-based chemotherapy regimens, with few other impactful therapeutic options. The past 2 years have seen a remarkable shift in the therapeutic landscape of mUC, with 5 novel immunotherapy agents receiving FDA approval for mUC, including first-line and second-line postplatinum settings. There are now many important clinical trials ongoing seeking to answer how best to use chemotherapy, immunotherapy, and targeted therapy agents in patients with mUC. Here we review the current standard of care for patients with mUC based on published data from the past 2 years, and look forward toward future research directions.